SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid mixed signals, with community frustration mounting over its stock performance despite positive developments. While initial discussion revolved around rumors of Nvidia abandoning Intel's 18A process, the recent clearance of Nvidia's $5 billion investment in Intel and the company's partnership in the US Department of Energy's "Genesis Mission" for AI are fueling optimism among long-term bulls regarding its advanced foundry initiatives and US government support.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is trending as the community anticipates upcoming showcases at CES 2026 and Qubits26, expected to highlight its commercial quantum computing applications and progress. While many express bullish sentiment on its long-term potential in a critical future industry, others debate its high volatility, current valuation relative to revenue, and executive share sales.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is a major talking point following its announced inclusion in the S&P MidCap 400. This news is generating significant community excitement, anticipating increased institutional demand, enhanced visibility, and a potential short squeeze. Investors are highlighting its strong financial position and its critical role in the rapidly evolving agentic AI and automation sector as key drivers for future growth.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending following its acquisition by Sanofi, prompting widespread congratulatory messages among shareholders and discussions around the valuation of the deal. The acquisition, which enhances Sanofi's vaccine portfolio with Dynavax's Hepatitis B vaccine and shingles treatment, also fuels conversations regarding the implications for Vaxart due to their oral COVID-19 vaccine licensing agreement. This development provides a significant exit for long-term investors amid prior frustrations concerning management and shareholder value.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending following its strategic acquisitions, notably a pivot into the healthcare sector with biotech and wild ginseng resources, alongside earlier moves in EV charging and smart tech. This aggressive diversification is fueling a polarized debate, with proponents highlighting the low float and asset-backed growth potential, while skeptics caution about its history as a volatile Chinese microcap. The stock is also gaining attention amid a broader market rotation where capital is shifting from crowded mega-cap tech into under-the-radar small-cap plays.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to multiple strategic partnerships focused on deploying its advanced thin-film solar technology across aerospace, defense, and terrestrial applications. The community is actively discussing the stock's significant price and volume surges, viewing it as a high-potential speculative play driven by the burgeoning space economy and demand for resilient power in extreme environments.

Dolomite

Dolomite (DOLO) is generating significant buzz as its onchain matrix, emphasizing fully on-chain NAV and planned oracle feeds, is attracting trust signals from larger holders. The community is actively accumulating during recent pullbacks, with many expressing strong bullish sentiment and anticipating a substantial upward move, drawing comparisons to other tokens that have recently seen considerable gains. This widespread optimism positions DOLO as a potential key runner in the broader altcoin market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Ascendiant Capital Markets upped their target price on shares of Oncobiologics from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Monday...

Oncobiologics (NASDAQ:OTLK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oncobiologics from a "strong sell" rating to a "hold" rating in a research note on Saturday...

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of +4.35% and -101.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Oncobiologics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Oncobiologics (NASDAQ:OTLK - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of...

Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK) will be releasing its Q4 2025 earnings before the market opens on Friday, December 26. (View Earnings Report at...

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Analysts

Shares of Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. One...

Oncobiologics (NASDAQ:OTLK) Stock Price Up 4.6% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Shares Up 4.6% - Time to Buy...

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Still a Buy?

Oncobiologics (NASDAQ:OTLK) Trading Up 5.9% - Should You Buy...

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Equity

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc